MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
News

Potential Changes to MS Treatment Access in Australia

MStranslate
July 2, 2026
Treatments
AHSCT in MS

MS Auckland Webinar: AHSCT as a Treatment for MS

MStranslate
June 18, 2026
Research, Stem Cells, Treatments

MS Auckland Webinar: Remyelination Research in MS

MStranslate
April 15, 2026
Cambridge, Remyelination, Research
two doctors, a man and a woman, examine an MRI image of the brain

FDA Decision On Tolebrutinib

MStranslate
January 12, 2026
Clinical Trials
A pair of hands around a crystal ball that has the year 2026 written inside it.

Multiple Sclerosis Research In 2026

MStranslate
January 5, 2026
Progressive MS, Remyelination, Treatments

Understanding the Different Outcomes of Optic Neuritis

MStranslate
April 29, 2014
Neuroimaging, Research
Optic neuritis (inflammation of the optic nerve) is a common side-effect of multiple sclerosis (MS) and leads to many sight-related difficulties, including blurriness, impaired colour recognition and problems...

An Introduction to the PrevANZ Trial

MStranslate
March 28, 2014
Lifestyle, Research, Vitamin D
Filmed during our MSBase Feature Week, this short video with Associate Professor Helmut Butzkueven introduces PrevANZ, a Multiple Sclerosis Research Australia led study investigating the role Vitamin D...

Fingolimod After Natalizumab & Short-term Relapse Risk

MStranslate
March 27, 2014
Fingolimod, Natalizumab, Research, Treatments
Dr Vilija Jokubaitis et al Natalizumab (Tysabri) is an antibody used for the treatment of multiple sclerosis (MS). It is currently the strongest drug available for the treatment of MS, however, it has also...

An Introduction to MSBase by A/Prof Helmut Butzkueven

MStranslate
March 25, 2014
Research
MSBase is an international multiple sclerosis (MS) registry that is helping answer many questions about MS. In this short video, Associate Professor Helmut Butzkueven (neurologist, MS researcher) explains...

Sex as a Determinant of Relapse Incidence & MS Progression

MStranslate
March 20, 2014
Research
Dr Tomas Kalincik et al Relapses of MS activity present with worsening of neurological symptoms and are usually followed by periods of stability. These are a defining feature of relapsing-remitting MS, the...
collaboration

MStranslate and Melbourne Brain Centre Announce Collaboration

MStranslate
February 20, 2014
Collaboration
MStranslate is excited to announce a new collaboration with the Melbourne Brain Centre at Royal Melbourne Hospital (MBC@RMH).  This opportunity follows MStranslate's presentation to the Melbourne Brain...

Google Hangout – Multiple Sclerosis Q&A

MStranslate
February 18, 2014
Research, Treatments
The first Google Hangout gave members of our community an opportunity to chat with MS researcher and MStranslate co-founder, Brett...

Is There a Link Between Type 1 Diabetes and Multiple Sclerosis?

MStranslate
January 24, 2014
Research, Type 1 Diabetes
By Brett Drummond Recently, we had a member of our community ask us whether there was a link between Type 1 diabetes (T1D) and MS. In response, here is a short summary of what is currently known on the...

Are Viral Infections Involved in Causing MS?

MStranslate
January 22, 2014
Epstein-Barr virus, Research
By Brett Drummond It is generally accepted that multiple sclerosis is an autoimmune disease, that is, a disease that arises from the body’s own immune system attacking and destroying the myelin sheath that...

Multiple Sclerosis Treatments Can Decrease Flu Vaccine Effectiveness

MStranslate
January 20, 2014
Treatments
By Brett Drummond Most current treatment options for MS involve altering and often suppressing the immune system. In many instances, this leads to an increased susceptibility to infection. Therefore,...
  1. 27
  2. 28
  3. 29
  4. 30
  5. 31
  6. 32
  7. 33

Recent Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Jun    

Archives

Categories

Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.